Business Context and Reporting Period
This Form 10-Q is a combined quarterly report for Corteva, Inc. and its wholly-owned subsidiary, EIDP, Inc., for the period ended March 31, 2025. Corteva operates in two reportable segments: Seed and Crop Protection. EIDP remains a separate reporting company but is fully consolidated within Corteva. The filing includes a restatement of EIDP's prior period cash flows due to a material weakness in internal controls regarding the classification of intercompany transactions.
Key Financial Metrics
| Metric (in millions) | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $4,417 | $4,492 |
| Cost of Goods Sold | $2,342 | $2,550 |
| Gross Margin | 47.0% | 43.2% |
| Operating EBITDA (Non-GAAP) | $1,189 | $1,034 |
| Net Income (GAAP) | $656 | $423 |
| Diluted EPS (GAAP) | $0.95 | $0.60 |
| Operating EPS (Non-GAAP) | $1.13 | $0.89 |
| Cash from Operations (Continuing) | $(2,101) | $(2,606) |
| Total Debt | $4,083 | $4,640 |
| Cash & Equivalents | $2,008 | $1,505 |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 2% year-over-year, driven by a 5% unfavorable currency impact (Brazilian Real, Turkish Lira, Euro), partially offset by a 2% volume increase and 1% price increase.
- Profitability: Net income increased 55% to $656 million, primarily due to lower restructuring charges ($22 million vs. $75 million), improved cost of goods sold (53% of sales vs. 57%), and a lower effective tax rate (14.9% vs. 22.0%).
- Segment Performance:
- Seed: Sales down 2%; Operating EBITDA up 13% ($842 million) due to pricing gains and cost benefits.
- Crop Protection: Sales down 2%; Operating EBITDA up 22% ($377 million) driven by volume growth and raw material deflation.
- Liquidity: Operating cash flow usage improved (less negative) by $505 million, driven by favorable changes in accounts payable and deferred revenue. Total debt increased to $4.08 billion due to higher short-term borrowings for working capital.
Guidance, Outlook, Risks, and Unusual Items
- Restructuring: The "Crop Protection Operations Strategy Restructuring Program" expects total pre-tax charges of $650–$700 million. $487 million has been recorded to date, with actions expected to be substantially complete by end of 2026. Expected run-rate savings are $180 million by 2027.
- Capital Allocation: The company returned $385 million to shareholders in Q1 via dividends ($0.17/share) and share repurchases ($270 million). A $3 billion buyback program was authorized in November 2024.
- Legal & Environmental Risks:
- PFAS Litigation: Significant exposure remains regarding legacy EIDP businesses (PFOA/GenX). A Memorandum of Understanding (MOU) with Chemours and DuPont establishes a cost-sharing arrangement for PFAS liabilities, with Corteva's estimated share capped at approximately $600 million of a $2 billion potential pool.
- Antitrust: Ongoing FTC investigation and multi-district litigation regarding Crop Protection pricing and competition; trials expected to begin in 2026.
- Intellectual Property: Disputes with Bayer regarding E3 soybeans and AAD-1 herbicide resistance technology.
- Internal Controls: EIDP disclosed a material weakness in internal controls over financial reporting related to the classification of intercompany cash flows, resulting in a restatement of prior period cash flow statements. Remediation is underway.
Investor Verification Checklist
- Restatement Impact: Verify the specific adjustments made to EIDP's Q1 2024 cash flow statement and confirm the remediation plan for the material weakness in internal controls.
- PFAS Liability Exposure: Review the MOU terms with Chemours and DuPont to understand the specific triggers for Corteva's $600 million estimated share of PFAS liabilities and the status of the MOU Escrow Account.
- Working Capital Seasonality: Assess the sustainability of the $2.1 billion operating cash outflow, which is typical for Q1 due to seasonal seed financing, and monitor the drawdown of the $5.5 billion committed credit facilities.
- Restructuring Progress: Track the execution of the Crop Protection restructuring program against the $650–$700 million charge estimate and the timeline for achieving $180 million in run-rate savings.
- Antitrust Litigation: Monitor the status of the FTC lawsuit and private class actions, specifically the dismissal of federal damages claims and the timeline for state-level trials in 2026.